RT Journal Article
SR Electronic
T1 Immunogenicity of a third dose of BNT162b2 to ancestral SARS-CoV-2 & Omicron variant in adults who received two doses of inactivated vaccine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.20.22269586
DO 10.1101/2022.01.20.22269586
A1 Nancy H. L. Leung
A1 Samuel M. S. Cheng
A1 Mario Martín-Sánchez
A1 Niki Y. M. Au
A1 Yvonne Y. Ng
A1 Leo L. H. Luk
A1 Karl C. K. Chan
A1 John K. C. Li
A1 Yonna W. Y. Leung
A1 Leo C. H. Tsang
A1 Sara Chaothai
A1 Kelvin K. H. Kwan
A1 Dennis K. M. Ip
A1 Leo L. M. Poon
A1 Gabriel M. Leung
A1 J. S. Malik Peiris
A1 Benjamin J. Cowling
YR 2022
UL http://medrxiv.org/content/early/2022/03/31/2022.01.20.22269586.abstract
AB Background Limited data exist on antibody responses to mixed vaccination strategies involving inactivated COVID-19 vaccines, particularly in the context of emerging variants.Methods We conducted an open label trial of a third vaccine dose of an mRNA vaccine (BNT162b2, Fosun Pharma/BioNTech) in adults aged ≥30 years who had previously received two doses of inactivated COVID-19 vaccine. We collected blood samples before administering the third dose and 28 days later, and tested for antibodies to the ancestral virus using a binding assay (ELISA), a surrogate virus neutralization test (sVNT) and a live virus plaque reduction neutralization test (PRNT). We also tested for antibodies against the Omicron variant using live-virus PRNT.Results In 315 participants, a third dose of BNT162b2 substantially increased antibody titers on each assay. Mean ELISA levels increased from an optical density (OD) of 0.3 to 2.2 (p<0. 001), and mean sVNT levels increased from an inhibition of 17% to 96% (p<0.001). In a random subset of 20 participants, the geometric mean PRNT50 titers rose very substantially by at least 24 fold from Day 0 to Day 28 against the ancestral virus (p<0.001) and rose by at least 11 fold against the Omicron variant (p<0.001). In daily monitoring, post-vaccination reactions subsided within 7 days for over 99% of participants.Conclusions A third dose of COVID-19 vaccination with an mRNA vaccine substantially improved antibody levels against the ancestral virus and the Omicron variant with well-tolerated safety profile, in adults who had received two doses of inactivated vaccine 6 months earlier.Summary In this open label trial of Chinese adults aged ≥30 years who received two doses of inactivated COVID-19 vaccine 6 months earlier, third-dose mRNA vaccine substantially improved antibody levels against the ancestral virus and Omicron variant with well-tolerated safety profile.Competing Interest StatementBJC consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Moderna, Pfizer, Roche and Sanofi Pasteur. The authors report no other potential conflicts of interest.Clinical TrialNCT05057182Funding StatementThis project was supported by the Theme-based Research Scheme T11-712/19-N of the Research Grants Council of the Hong Kong Special Administrative Region, China (BJC). BJC is supported by a RGC Senior Research Fellow Scheme grant (HKU SRFS2021-7S03) from the Research Grants Council of the Hong Kong Special Administrative Region, China. The funding bodies had no role in the design of the study, the collection, analysis, and interpretation of data, or writing of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Institutional Review Board of the University of Hong Kong/ Hospital Authority Hong Kong West ClusterI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized raw data and R syntax to reproduce all the analyses, figures and tables in the published article will be made available after publication.